WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Risk of Mineral Bone Loss and Serum Parathyroid Hormone in People with Chronic Renal Illness

Prasanthi Rayaprolu[1], Prof.Dr.Jaya Jain[2]

[1]Research Scholar, Malwanchal University, Indore.
[2]Research Supervisor, Malwanchal University, Indore.

Introduction

Chronic kidney disease (CKD)-mineral and bone disorder (MBD) is a clinical ailment characterised by a systemic impairment of mineral and bone metabolisms. These signs may occur alone or in combination with this condition: A lack of vitamin D, problems with bone formation and repair, calcium accumulation in arteries, and other soft tissue all contribute to brittle bones. In most cases of chronic renal disease, the damage to bones is not immediately apparent. Usually, MBD symptoms don't appear until the latter stages of the illness. Secondary hyperparathyroidism (SHPT), characterised by elevated PTH levels, affects the vast majority of people with CKD. Patients with early-stage chronic kidney disease (CKD), when medication may be most helpful, are significantly underdiagnosed and undertreated for SHPT. Calcium, phosphorus, and the calcium-x-phosphorus product tend to rise when SHPT has reached an uncontrolled stage. Metabolism-related bone disorders in chronic renal failure In time, SHPT led to the development of high-turnover bone disease. Increased PTH levels and the presence of hyperplastic parathyroid glands have long been recognised as indicators of future renal failure (CKD). Chronic kidney illness is linked to decreased bone turnover (adynamic bone disease). Low-turnover bone disease, characterised by an exceedingly slow speed of bone creation, is common among people with renal failure, particularly those on dialysis. Hyperparathyroidism results from a combination of factors, including an enlarged parathyroid gland, alterations inside the parathyroid gland that increase PTH secretion, and skeletal resistance to the effects of PTH.

This study aimed to find a non-invasive way to measure iPTH levels in the blood of CKD patients so that cases of MBD might be diagnosed earlier. The Kidney Disease Improving Global Outcomes (KDIGO) guidelines say that patients with an eGFR of 50 mL/min/1.72 m2 should have their serum phosphorus, calcium, parathyroid hormone (PTH), and alkaline phosphatase (AP) measured regularly to find out if there are any abnormalities and how bad they are, as well as how fast CKD is getting worse.

Methodology

Patients who agreed to take part in this study were hospitalised to the hospital between January 2021 and December 2021 and received care in the hospital's Dialysis Unit, Nephrology Outpatient Clinic, or general medicine wards. Two hundred participants with chronic renal disease were included, half of whom were undergoing hemodialysis and the other half were not.

Acceptance criteria

Those with an eGFR of 50 mL/min/1.72 m2 or less have chronic renal disease, as described by the Kidney Disease: Improving Global Outcomes programme. Kidney function expressed in millilitres per minute per square metre was used to provide this assessment of the patient's condition. It is likely that you have contracted kidneys if an ultrasound indicates that their diameter is smaller than 7 centimetres or if you have lost corticomedullary differentiation and have increased echogenicity. Kidney enlargement is a common sign of several diseases, including autosomal dominant polycystic kidney disease, diabetic nephropathy, and amyloidosis.

Criteria for omission

Chronic kidney illness, acute kidney damage, and cancer of the urinary tract or testicles all fall under this category.Many other indicators, such as blood urea level (BUL), serum creatinine level (SCR), serum electrolytes, calcium, phosphorus, alkaline phosphatase (ALP), and intact parathyroid hormone (iPTH), were checked during the thorough clinical workup performed on each patient. Each patient had both transvaginal and transabdominal ultrasounds. PTH concentrations were determined using the standard radioimmunoassay technique. The bulk of PTH's biological action is located in the hormone's middle and COOH terminal portions, which are particularly susceptible to this technique. Not only do active substances accumulate in the body when the kidneys aren't functioning correctly, but so do other waste products. Due to its excellent specificity and sensitivity, an intact PTH is the diagnostic standard for SHPT. The diagnosis of MBD in our patients was supported across many platforms, including clinical observations, biochemical analyses, and imaging studies. Chi-square tests, together with sensitivity, specificity, positive predictive value (PPV), and negative

predictive value (NPV), were used to determine the statistical significance of the observed associations (CIs).

Results

Patients between the ages of 41 and 55 accounted for 40% of the total, with 43% having chronic kidney disease for less than a year, 51% for between a year and four years, and 22% for more than four years. This finding may indicate that the presence of MBD was unrelated to the duration of CKD. One study found that 83% of CKD patients had MBD, whereas 23% did not. The majority (69%) of these 41 patients were already receiving hemodialysis for maintenance purposes, whereas the remaining 36% were either new patients or those who had previously stopped receiving hemodialysis. A total of 46 of the CKD hemodialysis patients (out of 200) developed MBD, whereas only 6 did not. It was revealed that 145 of the 200 CKD patients who had never received hemodialysis had MBD, whereas only 19 did not.

The majority of chronic kidney disease (CKD) patients (63%), had renal failure brought on by hypertension and diabetic nephropathy. Among those with CKD, 192 out of 200 showed elevated iPTH levels in their blood. A higher iPTH level was associated with an increased risk of MBD (84.2 percent). When comparing patients with normal and elevated iPTH levels, the findings indicated that 83.1% of those with elevated iPTH had MBD, whereas only 8% of those with normal iPTH did (3 = 6.11,(P = 0.02), sensitivity 97.0%, specificity 18.43%, PPV 82.7%, and NPV 81.4s). Only 8% of patients with normal iPTH levels developed MBD, and the mean and standard deviation for iPTH in those with MBD was 163 (37.18), while in those without MBD it was 99.1 (Z = -2.7, P > 0.0001). (. There was a correlation between elevated iPTH and MBD-measured BUL concentrations.

Blood markers such haemoglobin, creatinine, uric acid, phosphorous, calcium, and alanine aminotransferase were measured using MBD and shown to have no correlation with one another (ALP).

Conclusion

Therefore, elevated parathyroid hormone levels in the blood are a sensitive but not necessarily accurate predictor of MBD in CKD. When it comes to diagnosing and treating CKD-MBD, KDIGO's evidence-based recommendations highlight areas where further study is required. Biological markers, individual traits, and co-occurring diseases are just a few of the many variables that might affect the severity of this ailment. As of now, there aren't any standardised approaches to treating CKD-MBD. Instead, doctors should monitor several CKD-MBD indicators to individualise therapy for each patient.

Reference

1) Felsenfeld AJ, Rodríguez M, Aguilera-Tejero E: Dynamics of parathyroid hormone secretion in health and secondary hyperparathyroidism. Clin J Am Soc Nephrol 2: 1283–1305, 2007pmid:17942777

2) Kraenzlin ME, Meier C: Parathyroid hormone analogues in the treatment of osteoporosis. Nat Rev Endocrinol 7: 647–656, 2011

3) Lamb EJ, Vickery S, Ellis AR: Parathyroid hormone, kidney disease, evidence and guidelines. Ann Clin Biochem 44(Pt 1): 1–4, 2007

4) Massry SG: Is parathyroid hormone a uremic toxin? Nephron 19: 125–130, 1977pmid:895963

5) Rodriguez M, Lorenzo V: Parathyroid hormone, a uremic toxin. Semin Dial 22: 363–368, 2009

6) Sprague SM: Renal bone disease. CurrOpin Endocrinol Diabetes Obes 17: 535–539, 2010

7) Covic A, Kanbay M, Voroneanu L, Turgut F, Serban DN, Serban IL, Goldsmith DJ: Vascular calcification in chronic kidney disease. Clin Sci (Lond) 119:111–121, 2010.

8) Ketteler M, Rothe H, Krüger T, Biggar PH, Schlieper G: Mechanisms and treatment of extraosseous calcification in chronic kidney disease. Nat Rev Nephrol 7: 509–516, 2011

9) Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G, Kidney Disease: Improving Global Outcomes (KDIGO): Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69: 1945–1953, 2006pmid:16641930

10) London G, Coyne D, Hruska K, Malluche HH, Martin KJ: The new kidney disease: Improving global outcomes (KDIGO) guidelines—expert clinical focus on bone and vascular calcification. Clin Nephrol 74: 423–432, 2010pmid:21084045

11) Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL: Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int 71: 31–38, 2007